BBC250117P24000
- 0.00
- 0.000.00%
Etfis Ser Tr I Virtus Lifesci Biotech Clinical Trials Newsroom
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Virtus LifeSci Biotech Clinical Trials ETF Declares Annual Distribution of $0.2394
D. Boral Capital Initiates Coverage On Omeros With Buy Rating, Announces Price Target of $36
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Chardan Capital Initiates Coverage On Prothena Corp With Buy Rating, Announces Price Target of $40
Needham Reiterates Hold on Omerosto Hold
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant
Prothena Corp Analyst Ratings
Gold Falls Sharply, Lamb Weston Shares Plunge
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
Omeros Shares Are Trading Higher After the Company Announced That Narsoplimab Met Its Primary Trial Endpoint and Will Resubmit Its Narsoplimab Biologics License Application to the FDA.
Wells Fargo Maintains Equal-Weight on Zymeworks, Raises Price Target to $14
This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
Wells Fargo Downgrades Viridian Therapeutics to Equal-Weight, Announces $27 Price Target
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted For Relutrigine In Dravet Syndrome; Praxis Plans To Initiate An All-DEE Trial (EMERALD), Inclusive Of Dravet Syndrome, In 1H2025
Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views
Annexon Analyst Ratings
Biggest Stock Movers Tuesday: ZYME, EVGO, and More